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Abstract  
Introduction: Diabetes mellitus (DM) is a metabolic disorder characterised by 
elevated blood glucose levels, altered metabolism of carbohydrates, lipids and 
proteins. It also increases the risk of complications from cardiovascular 
diseases. In 2013 it is estimated that 6% of the world’s population suffer from 
diabetes and this is increasing at an alarming rate. The current antidiabetic 
medications are effective in controlling blood glucose levels, however, they are 
associated with weight gain, hypoglycaemic episodes, inflammation and build-
up of free radicals and toxins. Some of the current medications include 
metformin, sulfonylureas, glitazones, sodium-glucose co-transporter 2 
inhibitors, insulin, dipeptidyl peptidase 4 inhibitors and incretin mimetics. 
Exenatide is a new antidiabetic drug, and one of the most commonly used 
Incretin Mimetics, which stimulates insulin secretion, suppresses glucagon 
secretion and inhibits gastric emptying, which results in reduced appetite and 
food intake. It also has beneficial antioxidant and antiradical effects. However, 
exenatide has poor oral absorption and stability profile which limits its clinical 
benefits in diabetes treatment. Thus, this study aimed to evaluate the stability 
and degradation profiles of exenatide at various pH values and temperatures.  
Methodology:  
An HPLC method was developed to determine the concentrations of exenatide 
in various aqueous formulations. Exenatide concentrations were measured  
using an HPLC system equipped with UV-detection set at 225nm and the 
mobile phase consisted of 36% acetonitrile, 64% Milli-Q water, 0.1% 
trifluoroacetic acid and 10mM triethylamine with a final pH of 3.00. The stability 
of exenatide was investigated in pH 2.00 (chloroacetate), 3.50 (citrate), 4.50 
(acetate), 6.00 (citrate), 7.00 (citrate), 8.00 (Tris), and 10.00 (ethanolamine) at 
40 °C and buffer concentration of 10mM. In order to obtain the shelf-life, 
exenatide stability was also investigated at pH 2.00, 4.50 and 10.00 at 35 °C 
and 45 °C. The effect of ionic strength on the stability of exenatide was also 
investigated.  
Results and discussion: The marketed formulation of exenatide has a pH 
value of 4.50. However, exenatide is most stable at pH 6.00 and the reaction 
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rate was highly temperature dependent.  Exenatide degradation followed first 
order kinetics under all conditions employed. At 40 °C, exenatide was most 
stable at pH 6.00 with a reaction rate constant of 1.11x10-3 h-1 while it was least 
stable at pH 10.00 with a reaction rate constant of 1.89x10-2 h-1. The reaction 
rate constant at pH 4.50 is 1.15x10-2 h-1, which is considerably higher than at 
pH 6.00. Exenatide had the highest activation energy value at pH 10.00 (138±7 
kJ/mol) followed by pH 2.00 (124±3 kJ/mol) and the lowest at pH 4.50 (121±5 
kJ/mol). There was no significant effect of changing the ionic strength on 
exenatide stability or degradation suggesting reasonable resistance to addition 
of electrolyte.  
Conclusion: Exenatide was more stable at pH 6.00, compared with its current 
marketed formulation (Byetta) which is formulated at pH 4.50. The reason why 
exenatide was formulated at pH 4.50 has not been disclosed by the 
manufacturer. Future studies should aim at investigating a more stable 
exenatide formulation and a more convenient route of administration.  
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1 General Introduction 
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Diabetes mellitus 
1.1 Introduction 
Diabetes mellitus (DM), often referred to as diabetes, is a metabolic disorder 
characterised by hyperglycaemia, altered metabolism of carbohydrates, lipids 
and proteins, and an elevated risk of complications from cardiovascular 
disease (1). In DM, blood glucose levels are elevated, either because the 
pancreas does not produce enough insulin or because cells do not respond to 
existing insulin. The main symptoms include polydipsia (excessive thirst), 
polyuria (frequent urination), polyphagia (increased hunger), feeling lethargic, 
and slow healing of cuts and wounds (1). DM can lead to microvascular and 
macrovascular complications such as retinopathy, nephropathy and 
atherosclerosis (2-4).  
DM is classified as Type 1 diabetes (T1D), Type 2 diabetes (T2D) or 
gestational diabetes (GD). T1D is an autoimmune disease manifested by the 
destruction of the -cells of the pancreas resulting in a partial or complete lack 
of insulin production and the inability of the body to control glucose 
homeostasis (5). T1D is also known as juvenile-onset diabetes because it 
manifests at a young age. As it requires the patient to inject insulin to 
supplement the partial or complete lack of insulin production by the pancreas, 
it is also called insulin-dependent diabetes mellitus (IDDM) (6). T2D, formerly 
known as noninsulin-dependent diabetes mellitus (NIDDM) or adult-onset 
diabetes, is a metabolic disorder with onset most common in middle age and 
later life (7). T2D may be controlled by diet and exercise and, unlike T1D, does 
not always require the use of insulin (8). However, the term “noninsulin-
dependent” is a misnomer since many patients require insulin therapy at some 
time in the course of their disease (9). T2D is often associated with obesity, 
hypertension and insulin resistance (10) and can result in the complete 
destruction of -cells of the pancreas leading to the need to inject insulin similar 
to that in T1D (11). Moreover, GD occurs in pregnant women especially during 
third trimester (12, 13). Women who develop GD are at higher risk of 
developing T2D after giving birth (14, 15). An Australian study has found that 
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women who had GD are about 10 times more likely to develop T2D compared 
to those who did not develop GD (16). 
In 2010, the prevalence of DM worldwide was estimated to be 285 million, 
which accounted for 6 % of the world’s population, and by 2030, this value is 
expected to increase to 8% (16). The predominant form of diabetes is T2D and 
it accounts for 90% of all DM cases (16). Developing countries have a greater 
share of the increase in the prevalence of diabetes. This is possibly due to the 
increase in prevalence of overweight and obesity caused by the changes 
towards western food. Until 1990, T2D was rare in young people and in 
pregnant women, but this has changed and it is becoming more common.  
In Australia, diabetes is the 6th highest cause of death and the fastest growing 
chronic illness. Diabetic patients are twice as likely to have high blood 
pressure, cholesterol disturbances and heart disease. In 2013, it was 
estimated that 1 in 4 Australian adults has either diabetes or pre-diabetes (17), 
with one person being diagnosed every 5 minutes. Over 3.6 million Australians 
are diabetic or pre-diabetic and the prevalence is increasing by 7% every year. 
Diabetes costs Australia more than $15 billion a year and this is not including 
the emotional costs arising from higher mortality rate, impaired performance of 
workers with diabetes and lower life expectancy.  
Globally, diabetes affects more than 250 million people with more than half in 
the 40-65 age group (18, 19). It is predicted that the total number of diabetics 
will surpass all current predictions within the coming 20 years if no new or 
substantially better antidiabetic drugs are invented. New drugs need to be able 
to better control insulin secretion and glucose haemostasis, as well as being 
able to ameliorate diabetes-associated complications.  
1.1.1 Insulin secretion and glucose regulation  
Glucose is a major source of energy with the normal range in blood being 3.5-
6.0 mmol/l (20). When the body is at rest (also known as the basal state), the 
consumption of glucose is equal to its production and there is no net gain (21). 
When glucose is absorbed into the systemic circulation and the body is not 
utilising it for energy production, it is stored in the liver and muscles in the form 
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of glycogen (22). In healthy individuals, glycogen synthesis (glyconeogenesis) 
in tissues is stimulated by insulin (23). When the amount of glucose in the 
blood decreases, glycogen breaks down in the liver to glucose 
(glycogenolysis). In healthy individuals, feedback mechanisms ensure that 
glucose levels are under homeostatic control by balancing glyconeogenesis 
and glycogenolysis (24). The liver can also convert lactate to glucose via a 
process known as gluconeogenesis to further supply the required glucose to 
the blood when levels are low (24-26). Glyconeogenesis, glycogenolysis and 
gluconeogenesis are controlled by anabolic hormones released from the 
pancreas such as glucagon (from -cells) and insulin (from β-cells). Both 
hormones, glucagon and insulin, bind to specific receptors to trigger a chain 
of reactions that control glucose homeostasis (27-31). GLUT-2 (mainly in β-
cells) and GLUT-4 (mainly in skeletal muscles) are the dominant glucose 
transporters. In general, insulin activates GLUT transporters to become fully 
functional pores that are able to transport glucose molecules into tissues (32). 
The pancreas produces significant quantities of insulin which it stores in 
intracellular secretary granules. Upon granular stimulation from rising levels of 
glucose, these granules release their insulin content into the mesenteric veins 
(33, 34). The process of insulin secretion is different in healthy and diabetic 
patients. Normally, in healthy individuals, there are two phases of insulin 
secretion; first phase insulin secretion which starts immediately after the initial 
stimulus of raised glucose levels and second phase insulin secretion which 
starts shortly after the first phase, and has a shorter duration but greater 
magnitude. First phase insulin secretion occurs from -cells of the pancreas 
as a direct response to high influx of extracellular glucose (35, 36). When 
diabetic patients lack -cells (in T1D patients or T2D patients who lost their -
cells), both phases of insulin do not exist since there is a complete lack of 
functional -cells and insulin production. In T2D patients that have remaining 
functional -cells, the first phase of insulin secretion is impaired and further 
exposure to glucose results in a reduction in insulin secretion in the second 
phase due to the desensitization of -cells to glucose (11).       
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1.1.2 Pathogenesis of diabetes  
T2D develops in adult life most likely due to genetic and environmental factors 
(37) that lead to tissue desensitization to insulin. Environmental factors include 
high intake of saturated fat and glucose, low fibre content, lack of exercise and 
obesity (collectively known as the metabolic syndrome). Tissues lacking 
insulin sensitivity have poor expression of insulin receptors and hence have 
poor uptake of glucose on insulin stimulation. As a result, glucose remains free 
in the blood (38). Continuous stimulation of β-cells through hyperglycaemia or 
certain types of antidiabetic drugs can lead to tissue exhaustion and eventual 
cessation of insulin production due to tissue damage (39).   
1.1.3 Complications of diabetes  
DM increases the risk of developing complications which include 
gastroparesis, cardiovascular disorders such as platelet adhesion and 
atherosclerosis, oxidative stress, metabolic symptoms such as obesity, 
atherogenic dyslipidaemia, hypertension and insulin resistance, and 
cholecystitis (40-43). The vascular complications are caused by poor 
glycaemic control and may affect structure and functionality of the small blood 
vessels (microvascular) or the large blood vessels (macrovascular). The 
macrovascular complications include a two to four fold increase in the 
incidence of stroke, coronary heart disease (CHD) and peripheral vascular 
disease (44, 45). Peripheral vascular disease can lead to ulcerations, 
gangrene, and lower limb amputation (44). On the other hand, microvascular 
complication of diabetes mellitus include nephropathy, neuropathy, and 
retinopathy (44, 45). Diabetic nephropathy or kidney disease, is the primary 
cause of end stage renal disease (ESRD) (46). The biomarkers for 
nephropathy are elevated glomerular blood pressure and the presence and 
progressive increase of albumin levels in the urine (44). Approximately 15-20% 
of type 1 diabetes mellitus and 30-40% of T2D mellitus patients develop end 
stage renal disease (44). On the other hand, about 60% of diabetic patients 
develop diabetic neuropathy which makes it the most common long term 
complication of diabetes mellitus. It involves loss of sensation, weakness and 
pain and can lead to limb amputations (44, 47). The third microvascular 
diabetic complication is diabetic retinopathy which is caused by damage to 
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blood vessels in the retina and can lead visual impairment and blindness in the 
working population (48). Another complication of diabetes mellitus is 
periodontal and foot diseases which occur due to the impairment of the 
immune system caused by the diabetes. The immune system impairment lead 
to the body’s inability to fight pathogens including bacterial, fungal, protozoal 
and viral infections which if not diagnosed in time can lead to gangrene and 
limb amputations which accounts for more than 60% of nontraumatic lower 
limb amputations (44, 49).    
1.1.4 Drug therapy for Type 2 diabetes 
Antidiabetic drugs are commonly used and are effective in minimizing 
variations between peaks and troughs of blood glucose levels in diabetic 
patients. However, weight gain, obesity and associated inflammation as well 
as the build-up of free radicals and toxins, remain detrimental factors in the 
treatment of the disease and its complications (50-52). Current antidiabetic 
drugs aim at inducing insulin secretion and improving tissue-response to 
insulin which results in better glycemic control. Biguanides, thiazolidinedione 
and sulphonlyureas have been available in the market for many decades while 
newer drugs such as dipeptidyl peptidase-4 (DPP-4) inhibitors and incretin 
mimetics are now available and have shown great potential in the treatment of 
diabetes and its complications.  
1.2 Current drugs  
1.2.1 Biguanides 
Metformin (Figure 1.1), a drug from the biguanide class, was marketed in 1957 
as an orally administered drug to lower glucose levels in T2D patients (53, 54). 
Metformin works by improving the utilisation of glucose in the peripheral tissue 
and reducing the production of glucose in the liver (54, 55). Metformin is mainly 
absorbed from the small intestine with a bioavailability of 50-60%. It has a half-
life of 1.5-4.9 hours and a small affinity for plasma protein binding (53). The 
main route of elimination of metformin is via glomerular filtration rate and 
tubular secretion in the kidneys (53). Metformin does not undergo any hepatic 
metabolism and is eliminated unchanged in the urine (56). Metformin is the 
first line treatment for T2D. It reduces diabetes related events and mortality in 
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overweight diabetic patients and it does not cause hypoglycaemia and may 
result in weight loss which can be beneficial in diabetic patients (55).   
 
Figure 1.1: Chemical structure of metformin 
 
1.2.2 Sulfonylureas 
Sulfonylureas, chemical structure presented in Figure 1.2, were one of the first 
drugs to be marketed as an oral hypoglycaemic agents (57). They stimulate 
the β-cells in the pancreas to produce insulin (57, 58). They do that through 
antagonising adenosine triphosphate (ATP) sensitive potassium channels at 
the membrane of the pancreatic β-cells (59). They also have other effects 
including decreasing glucagon production, and reducing hepatic insulin 
clearance (51, 57). The first generation of sulfonylureas were tolbutamide, 
acetohexamide, chlorpropamide, and tolazamide (59). These drugs were then 
superseded by the second generation sulfonylureas which included gliclazide, 
glipizide, glibenclamide and the newer third generation agent glimepiride (58, 
59). Sulfonylureas may result in weight gain and the incidence of 
hypoglycaemic episodes. The risk of hypoglycaemia is increased in patients 
with hepatic or renal failure and the elderly (55). Gliclazide and glipizide are 
the least likely drugs from the sulfonylurea group to cause hypoglycaemia. 
They are often added to metformin if metformin alone does not adequately 
control blood glucose levels. They can cause weight gain and expected to 
reduce HbA1c by 10-20 mmol/mol (55).  
8 
 
 
Figure 1.2: Chemical structure of selected sulfonylureas.  
 
1.2.3 Thiazolidinediones 
Thiazolidinediones (TZD) or glitazones are a class of antidiabetic drugs that 
improve the metabolism in patients with T2D. The chemical structures of 
glitazones is presented in Figure 1.3. Their novel mode of action is through the 
activation of peroxisome proliferator-activated receptor gamma which is 
responsible for regulation of genes involved in the metabolism of glucose and 
lipid (55). They are referred to as insulin sensitisers because they improve 
insulin sensitivity. They decrease insulin resistance in muscle, adipose tissue 
and the liver (55, 60). They may also have potential benefit on the 
manifestation of insulin resistance syndrome (60). The drugs included in this 
class are pioglitazone and rosiglitazone (55). Glitazones are normally reserved 
for diabetic patients unable to take other antidiabetic medications. They are 
ineffective in up to 30% of patients and have serious side effects such as 
oedema, increased fracture risk and heart failure. They do not cause 
hypoglycaemia if used in monotherapy and they may lead to weight gain. The 
expected decrease in HbA1c by glitazones is 5-15 mmol/mol. Rosiglitazone 
may also increase the risk of ischaemic cardiovascular events.  
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Figure 1.3: Chemical structures of pioglitazone and rosiglitazone 
 
1.2.4 Acarbose 
Acarbose is an oral alpha-glucosidase inhibitor which is used in the 
management of T2D. Acarbose is an oligosaccharide (Figure 1.) which is 
acquired from fermentation processes of a microorganism, Actinoplanes 
utahensis. It exerts its effect by delaying the digestion of ingested 
carbohydrates which results in a smaller rise in blood glucose levels after 
meals. The reduction of plasma glucose levels leads to a decrease in the levels 
of glycosylated haemoglobin in patients with T2D. Acarbose can produce a 
reduction in HbA1c by 5-10mmol/mol and does not cause hypoglycaemia if 
used in monotherapy. Its poorly tolerated because of its gastrointestinal side 
effects therefore has a limited role in diabetes therapy. Acarbose has no effect 
on the weight of diabetic patients (55).  
According to a randomised control trial (STOP-NIDDM) published in 2002, 
Acarbose can be used to prevent or delay the conversion of impaired glucose 
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tolerance into T2D (61). Acarbose has similar efficacy and tolerability to 
metformin in Chinese patients with a new diagnosis of type two diabetic 
patients (62). 
 
Figure 1.4: Chemical structure of Acarbose. 
 
1.2.5 Sodium-Glucose cotransporter-2 (SGLT2) inhibitors 
1.2.5.1 Dapagliflozin 
Dapagliflozin (Forxiga®), Figure 1.4, selectively inhibits the sodium-glucose 
cotransporter 2 (SGLT2) which results in inhibition of renal glucose 
reabsorption and prompting the emission of glucose in the urine (63, 64)  as a 
result of urinary glucose excretion, hyperglycaemia may improve while also 
providing the benefits of weight control and weight loss (64). The drug was 
developed to be used as therapy for T2D that is independent from insulin (63, 
64). SGLT2 inhibitors may increase the risk of hypoglycaemia if used with 
insulin or sulfonylureas, however, they have a low risk if the drug is used alone. 
SGLT2 inhibitors should be avoided in patients with renal impairment. They 
can also increase the risk of urinary adverse effects such as urinary tract 
infection (UTI) and vaginal candidiasis due to the increased of glucose 
concentration in the urine. They can reduce HbA1c by 5-10 mmol/mol and can 
also lead to weight loss in diabetic patients (55). Dapagliflozin was studied as 
monotherapy in previously untreated type 2 diabetic patients whose 
hyperglycaemia was inadequately controlled by diet and exercise. The study 
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showed that there was a significant reduction in glycated haemoglobin 
(HbA1c) from base line in the treatment group compared to placebo (65). The 
Australian approval for dapagliflozin permits it to be used as monotherapy only 
in diabetic patients who cannot tolerate metformin, however, it can be 
employed as initial treatment in combination with metformin (66). The effect of 
dapagliflozin was investigated in type 2 diabetic patients who had insufficient 
glycaemic control with metformin alone. The finding of the study revealed a 
significant difference in the effect of dapagliflozin in the treatment group on 
HbA1c and the placebo group (67). 
 
Figure 1.4: Chemical structure of dapagliflozin 
 
1.2.5.2 Canagliflozin 
The second sodium-glucose co-transporter inhibitor approved in Australia is 
Canagliflozin (Invokana®). The chemical structure of canagliflozin the 
presented in Figure 1.5. Like dapagliflozin, it increases the excretion of glucose 
in the urine through the reduction of glucose reabsorption which leads to a fall 
in the blood glucose levels. The bioavailability of canagliflozin is around 65% 
and even though food does not affect bioavailability, it is recommended to take 
canagliflozin before breakfast to potentially decrease postprandial glucose 
levels (68). Canagliflozin increases the risk of hyperkalaemia in patients with 
moderate renal impairment, especially if they are taking ACE inhibitors or 
potassium-sparing diuretics (68). The safety and efficacy of canagliflozin as 
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monotherapy has been investigated in 584 T2D patients that has not been 
controlled by diet and exercise. The study concluded that treatment with 
canagliflozin enhanced glycaemic control, produced weight loss and was 
generally well tolerated in this group of patients (69). Another study explored 
the effect on canagliflozin as add on therapy to metformin. It was concluded 
that canagliflozin was associated with significant improvement in glycaemic 
control, weight loss and a low incidence of hypoglycaemia in type 2 diabetic 
patients (70). 
 
Figure 1.5: Chemical structure of canagliflozin 
 
 
1.2.6 Insulin 
Insulin is a protein that consists of 51 amino acids which are divided in to two 
peptide chains that are linked by disulphide bridges. It was discovered in 1921 
by Banting and Best, and since then it has become one of the most extensively 
studied molecules in biochemistry (71, 72). The chemical structure of insulin is 
shown in Figure 1.6.  
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Figure 1.6 Primary structure of human insulin 
 
Insulin is synthesised in the β cells of the pancreas as proinsulin, which is then 
enzymatically converted in the storage vesicle to insulin (72).  
In T2D patients, insulin is either given as a monotherapy or as a combination 
with other antidiabetic medications. Monotherapy regimens combine short and 
long acting insulin and given subcutaneously in a single dose or twice daily 
before morning and evening meals. If combined with other antidiabetic 
medications, long acting insulin is normally given once a day (55).  
 
1.2.7 Incretin system  
Incretin hormones which include glucose-dependent insulinotropic polypeptide 
(GIP) and glucagon-like peptide-1(GLP-1) play an important role in the 
disposal of absorbed glucose by stimulating the secretion of insulin from the 
pancreas (73, 74). They also increase B cell mass by promoting B cell 
proliferation and inhibiting apoptosis (75). GIP consists of 4- amino acids and 
is synthesised by the enteroendocrine K cells in the duodenum and jejunum 
while GLP-1 is made in the ileal and colonal enteroendocrine L cells (74). The 
amount of insulin secreted after an oral glucose load was three to four folds 
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that after an intravenous glucose load (76). This effect was attributed to the 
incretin hormones which are GIP and GLP-1 that are released from the gut 
(77). GLP-1 also controls glycaemia through other pathways such as the effect 
on glucose sensors, inhibition of glucagon secretion, inhibition of gastric 
emptying and reducing food intake (75). In the fasting state, GLP-1 levels are 
low but increase rapidly after eating. Enzymatic deactivation mainly by 
dipeptidyl peptidase-4 (DPP-4) and renal clearance causes a rapid decline in 
the concentration of GIP and GLP-1 (74). 
The incretin effect is lost or greatly reduced in patients with T2D (73, 76, 77). 
The secretion of GIP in T2D is normal but it lacks the glucose lowering effect 
due to the loss of normal GIP induced potentiation of second phase insulin 
secretion. The insulinotropic response to GLP-1 is intact and the circulating 
levels of postprandial GLP-1 are reduced (76, 77).   
To overcome the rapid degradation of GLP-1, two approaches have been 
developed. One is to increase the concentration of endogenous GLP-1 by 
inhibiting DPP-4 which is responsible for degradation of GLP-1, and the other 
is using agents that mimic the action of the incretin hormone GLP-1 (78). 
1.2.8 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors 
DPP-4 extensively and rapidly degrades the intestinal incretin hormone GLP-
1 (74, 79). It is therefore postulated that inhibiting DPP-4 enzyme can be used 
as a treatment for T2D by protecting the circulating levels of GLP-1 from 
degradation (79). Experiments have shown that administration of DPP-4 
inhibitors to pigs have protected exogenous and endogenous GLP-1 from 
degradation which improved insulin response to hyperglycaemia (79). DPP-4, 
also known as CD26 is serine peptidase which is widely present on many 
tissues such as kidney, liver, lung, lymphocytes, intestinal brush-border 
membranes, and endothelial cells (74, 77, 79). The 766 amino acids enzyme 
is a membrane –associate peptidase but also available in a soluble circulating 
form in the plasma (74, 80). It preferentially cleaves peptide with an alanine or 
proline moiety in the second N-terminal position (74, 79). Substrates for DPP-
1 include neuropeptides, gastrointestinal hormones, cytokines, and 
chemokines (74). Inhibitors of DPP-4 imitate many of the actions attributed 
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GLP-1 receptor agonists, including inhibition of glucagon and stimulation of 
insulin secretion, stimulation of βcells proliferation and inhibition of apoptosis 
(81). However, DPP-4 inhibitors do not reduce gastric emptying or cause 
weight loss, which could be due to the modest protection of postprandial levels 
of intact plasma GLP-1 seen after inhibition of DPP-4. Pharmaceutical 
companies have developed small-molecule DPP-4 inhibitors that exclusively 
and potently hinder DPP-4 activity after an oral dose. More than 80% of DPP-
4 activity is inhibited and some of the inhibition is maintained for 24 hours on 
once daily treatment (74, 82).  Sitagliptin (Januvia®) was the first marketed 
DPP-4 inhibitor followed by vildagliptin (Galvus®) which reached the European 
Union market in 2008. The bioavailability of both drugs is good and they have 
a reasonably long duration of action (76). Sitagliptin and vildagliptin can be 
used as a monotherapy where they have shown a considerable antidiabetic 
action, or in combination where they also improved the glycaemic control when 
added to other antidiabetic drugs such as sulfonylureas, metformin and 
thiazolidinediones. Studies have shown that metformin may improve GLP-1 
biosynthesis and secretion, and the combination with DPP-4 inhibitor may 
produce a more significant increase in GLP-1 concentration than that if either 
of the drugs is used alone (74). 
Figure 1.7: Chemical structure of the four DPP-4 inhibitors: sitagliptin, vildagliptin, 
saxagliptin, and alogliptin. 
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1.2.9 Incretin Mimetics 
Incretin mimetics are a new class of antihyperglycaemic agents that mimic the 
actions of endogenous incretin hormones such as glucagon-like peptide-1 
(GLP-1) (74, 77). GLP-1 is a gut derived hormone that stimulates insulin 
secretion and suppresses the secretion of glucagon. GLP-1 also inhibits 
gastric emptying and reduces appetite and food intake (83). Several GLP-1 
receptor (GLP-1R) agonists or GLP-1 analogues that are resistant to 
degradation by the enzyme DPP-4 have been developed. Liraglutide was 
developed by Novo Nordisc, and contains Arg34Lys substitution and glutamic 
acid and 16-C fatty acid addition to Lys26 (84, 85). Another GLP-1 receptor 
agonist, Lixisenatide, is manufactured by Sanofi, under licence from Zealand 
Pharma A/S, and marketed under the brand name Lyxumia® (86, 87). It is 
administered subcutaneously once daily and has a half-life of 2.8 hrs. It is a 
synthetic 44 amino acid peptide derived from exendin-4 and its resistance to 
degradation by DPP-4 is achieved by removing proline from the 38 position 
and adding 6 lysine residues. Lixisenatide has approximately four times the 
affinity for the human GLP-1R compared to the native GLP-1 peptide (88). 
There are other incretin mimetic drugs either available on the market or still 
under development by drug companies, but the first drug to come on the 
market in the incretin mimetic class is exenatide.  
1.3 Exenatide  
Exenatide was discovered by Amylin Pharmaceutical Inc., and is under license 
to Elli Lilly. It is marketed under the brand name Byetta®. Exenatide is the 
synthesized form of a peptide venom found in the saliva of the Gila Monster 
lizard and is degradation resistant (77, 89).  Figure 1.8 shows the differences 
between the chemical structures of human GLP-1, liraglutide, exenatide and 
lixisenatide (90).  
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Figure 1.8: The difference in amino acid sequence between the human glucagon-
like peptide-1 (GLP-1), liraglutide, exenatide and lixisenatide and other 
formulation changes to affect its bioavailability and elimination.  
 
Exenatide is a degradation resistant GLP-1 receptor agonist that is based on 
exendin-4 which is a 39 amino acid peptide found in the saliva of the 
Heloderma suspectum lizard (75). Roughly, 50% of the amino acid sequences 
are the same in both exendine- 4 and GLP-1 hormones, found in humans (74). 
The presence of the amino acid glycine at position 2 in the sequence of 
exenatide protects the peptide from being degraded by DPP-4 (75).  
Due to its improved pharmacokinetic profile, the potency of exenatide for 
glucose lowering is 3000 times more than native GLP-1 after intravenous 
administration (75, 91). Exenatide can activate the GLP-1 receptor and exert 
its glucoregulatory effect at a much lower concentration compared to 
endogenous GLP-1 (92). The effect of exenatide is dependent on glucose 
concentration, which means an extended release formulation is a suitable 
option in the treatment of T2D (92). Exenatide can be administered 
subcutaneously twice a day within 60 minutes of a meal, or once weekly using 
the extended release formulation (2). The extended release formulation of 
exenatide (exenatide QW or Bydureon (93)) incorporates the peptide into a 
matrix of a biodegradable polymer (92). The biodegradable polymer (poly(D,L-
lactide-co-glycolide; PLG)) is known to be safe for use in humans, and will 
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degrade over time producing a prolonged release of exenatide. The median 
peak plasma concentration of exenatide is reached 2.1 hours after 
subcutaneous administration. Exenatide has a volume of distribution of 28.3 L 
and a half-life of 2.4 hours. It is predominantly eliminated by glomerular 
filtration with subsequent proteolytic degradation and the apparent clearance 
of the drug is 9.1 L/hr (94). The iso-electric point of exenatide is reported to be 
4.2 (95).  
As an incretin mimetic or a GLP-1 receptor agonist, exenatide exerts 
glucoregulatory effects similar to that of GLP-1. These effects include glucose-
dependent improvement of insulin secretion, suppression of glucagon 
secretion, increased insulin sensitivity, reduction of food intake and promoting 
weight loss through the slowing of gastric emptying (96).  
There are many studies that have investigated the effectiveness of exenatide 
in conjunction with other antidiabetic drugs. A study by DeFronzo et al., 
investigated the effect of exenatide in patients taking the maximum therapeutic 
dose of metformin (96)(96). The study showed that exenatide was generally 
well tolerated and reduced HbA1c without causing any weight gain and 
incidents of hypoglycaemia. Another study, conducted by Buse et al., found 
that when exenatide was given to T2D patients failing to get optimal glycaemic 
control with the maximum effective dose of sulfonylureas, it significantly 
reduced HbA1c, was generally well tolerated and resulted in weight loss (97). 
In a placebo-controlled trial which included 217 T2D patients for more than 
three years, were given placebo, 5µg exenatide, or 10µg exenatide twice a 
day. This study has shown that adjunctive exenatide treatment resulted in 
sustained improvements in glycaemic control, cardiovascular risk factors, and 
hepatic biomarkers associated with progressive weight reduction (98). A study 
by Wu et al., investigated the effects of exenatide on inflammatory and 
oxidative stress markers in T2D patients. It concluded that treatment with 
exenatide twice daily led to a reduction in body weight and BMI, improvement 
in HbA1c, decrease in daily mean glucose, limiting of glycaemic excursion, and 
reduction in inflammatory and oxidative stress markers in patients with 
insufficient glycaemic control (99). Furthermore, Varanasi et al, concluded that 
treatment of T2D patients with exenatide has positively durable and persistent 
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effect on weight, HbA1c, systolic blood pressure, CRP, and the concentration 
of triglycerides. These beneficial effects were reversed within 6 months of 
ceasing the treatment (100).  
The effect of exenatide on T2D patients with congestive cardiac failure was 
investigated by D. Nathanson et al. and concluded that infusion of exenatide 
in male T2D patients with CHF increased cardiac index as a consequence of 
chronotropy. It also had a positive effect on pulmonary capillary wedge 
pressure and the drug was well tolerated (101).  
In addition, Linnebjerg et al. concluded that, exenatide slows gastric emptying 
in T2D patients (102). They also highlighted the importance of this effect on 
the absorption of medications in patients who are taking exenatide. They 
recommend those patients take their medications at a time when the effect of 
exenatide is minimum (i.e. midday or bedtime). However, in a study evaluating 
the effect of exenatide on digoxin concentration, exenatide decreased the 
mean plasma concentration of digoxin and delayed Tmax by 2.5 hours but did 
not change the steady state pharmacokinetics of digoxin or a clinical 
significance (103). Another study examined the effect of exenatide twice daily 
on warfarin pharmacokinetics, and found no significant effect (104).  
Exenatide has demonstrated in vitro to have a neuroprotective and neurotropic 
properties, however, the detail mechanisms of action remained unclear. Due 
to exenatide’s good safety profile in T2D patients and the encouraging results 
from Parkinson disease models in animals, recruitment of patients to evaluate 
the effect of exenatide on Parkinson’s disease has been completed (105). This 
suggests wide implications of the drug beyond glycemic control, and a huge 
potential in treating not only T2D but many associated complications. 
Despite all the potential benefits of exenatide in the treatment of T2D and other 
medical conditions, its route of administration and dosing frequency represent 
a significant drawback on its clinical use. The twice daily dosing and the pain 
and irritation cause by the injection may have a significant effect on patient 
compliance. Microencapsulation and other route of administration methods 
such as oral and sublingual formulation could significantly improve the clinical 
outcomes for the patients.   
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As a protein-based drug, exenatide is susceptible to degradation mainly by 
deamidation, oxidation and aggregation. 
1.4 Proteins  
Proteins are molecules constructed from amino-acids through peptide bonds 
(106). A protein chain can consist of 50 to 2000 amino acid and each chain of 
amino acids forms a secondary structure through folding (107, 108). The 
secondary structure can be either an α-helix or β-pleated sheets. Hydrogen 
bonds are the force that maintains the secondary structure. When the protein 
chain further folds on itself to form a three dimensional shape, it is referred to 
as a tertiary structure. The forces that hold the dimensional structure together 
are disulphide bridges, hydrogen bonds, ionic interactions and van der Waals 
forces (109).  
1.4.1 Degradation of proteins 
The pathways of degradation of proteins can be categorised into two different 
classes, physical and chemical degradation. Physical degradation involves 
changes to the higher structure (i.e. secondary structure and higher) of the 
proteins. These changes include denaturation, aggregation, adsorption to 
surfaces and precipitation (110). On the other hand, chemical degradation 
involves covalent bond breaking or formation resulting in new chemical 
entities. These chemical changes and instabilities include hydrolysis, 
deamidation and oxidation.  
1.4.1.1 Deamidation  
One of the most common routes of degradation of proteins is deamidation 
which occurs in proteins containing asparagine (Asn) moieties especially in the 
pH range 4-9 (111, 112). For deamidation in acidic conditions, direct hydrolysis 
of Asn takes place to produce only Asp and the reaction is subject to acid 
catalysis. On the other hand, for neutral to basic conditions (higher than pH 
6.00) deamidation occurs via an intramolecular cyclisation reaction 
(succinimide) with the emission of ammonia (113). The cyclic intermediate 
compound then hydrolyses to produce either normal aspartic acid (Asp) 
instead of Asn or iso-aspratic acid as shown in Figure 1.10 (112, 114). The 
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deamidation reaction is a two-step reaction and each step has a different 
reaction rate. Deamidation can also occur in glutamine (Gln) residue but at a 
lot slower rate than asparagine (115).  
 
Figure 1.9: Pathways for spontaneous deamidation, isomerization, and 
racemization for aspartyl and asparaginyl peptides (111). 
 
1.4.1.2 Oxidation  
Oxidation is another major chemical degradation pathway for proteins. The 
most susceptible amino acids to oxidation are methionine, cysteine, histidine 
tryptophan and tyrosine (113). The susceptibility of these amino acids to 
oxidation is due to their elevated reactivity to oxygen species. The presence of 
oxidising contaminants catalysed by light and transition metal ions is a major 
inducer of oxidation in proteins during manufacturing and storage (116). 
Methionine oxidation can result in the formation of sulfoxides which form under 
mild oxidative conditions or sulfones under harsher oxidation conditions (117).  
1.4.1.3 Aggregation  
One of the major problems that faces the development of pharmaceutical 
proteins is aggregation. Aggregation can lead to the production of antibodies 
and the development of serious side effects (118, 119). Protein aggregates 
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can range from dimers to sub-visible and visible particles (120). Aggregation 
and conformation of proteins can be influenced by pH conditions, different 
ions, and heat (121). 
1.5 Possible degradation sites for exenatide 
Figure 1.10 shows that exenatide has three sites, which are susceptible to 
degradation. Asp (red) and Met (blue) are susceptible to hydrolysis and 
oxidative degradation respectively. Asn (green) is known to be vulnerable to 
deamidation reactions.  
 
Figure 1.10: Chemical structure of exenatide with possible degradation sites. 
 
Thus, in order to quantitate degradation, stability testing can be carried out 
examining the effects of ionic strength, temperature and pH, in vitro. 
 
1.6 Formulation and stability of exenatide 
An investigation of the stability profile of exenatide in aqueous solutions is yet 
to be published. However, there are a few studies that have recently been 
published which investigate the stability of exenatide in microspheres and 
microcapsules. The most common method of microencapsulation of exenatide 
used poly(D,L-Lactic-co-glycolic acid) commonly referred to as PLGA. These 
studies investigated the effect of PLGA on the bio-stability and the 
pharmacokinetics of the drug. Qi et al. compared the properties of exenatide 
loaded PLGA microspheres, that are formed by either ultrasonication or 
homogenisation methods. They concluded that PLGA microspheres formed by 
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the homogenisation method were more appropriate for two-week sustained 
release. On the other hand, he found the ultrasonication method to be more 
suitable for longer time release, and may be used once monthly (122).  Liang 
et al. studied the effect of PLGA and solution media on the degradation of 
exenatide. The study concluded that solutions containing solvents such as 
dimethyl sulfoxide has a strong impact on the conformation state and the 
stability of exenatide. Furthermore, higher pH accelerates the degradation of 
exenatide, due to promoting the interaction between PLGA and the peptide 
leading to the formation of acylated products (123). However, none examined 
the underlying stability of exenatide.  
 
1.7 Ionic strength 
Ionic strength of a solution is a measure of the concentration of all ions in that 
solution. The ionic strength is calculated using the following equation (Equation 
1.1)  
 µ =1/2∑ciz2i      Equation (1.1) 
 
Where µ is ionic strength, Ci is the molar concentration of ion i (M), Zi is the 
charge number of that ion, and the sum is for all the ions in the solution. The 
ionic strength of a solution can influence the rate of degradation of a drug 
according to the following equation (Equation 1.2)  
log k = log k0 +1.02 ZA ZB √µ     Equation (1.2) 
 
Where ZA and ZB are the charges carried by the reacting species in solution, µ 
is the ionic strength, k is the rate constant of degradation, k0 is the rate constant 
at infinite dilution (124). 
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By plotting the logarithm of the reaction rate constant against the square root 
of the ionic strength, it can be determine whether an increase in ionic strength 
can lead to an increase, decrease, or has no effect on the rate of degradation. 
This effect is shown in Figure 1.11. 
 
The ionised species of a buffer may also have a catalytic effect on the rate of 
reaction above any pH effect exerted by the buffer. Such an effect is 
temperature-dependant.  
 
1.8 Effect of temperature on kinetics of degradation 
Data obtained under accelerated temperatures for temperature-dependent 
reactions allows the prediction of the stability of a drug at determined shelf-life 
temperatures. The relationship between temperature and reaction rate is 
expressed in the Arrhenius Equation:  
k=Ae-(Ea/RT)      Equation (1.3)  
    
Figure 1.1: Effect of ionic strength on degradation rate 
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Where, k is the specific rate constant, A is the frequency factor (total number 
of collisions) and is an index of reactive species in the activated state, R is the 
universal gas constant (8.314 joules degree-1 mol), T is the temperature in 
Kelvin, Ea is the activation energy. e-Ea/RT indicates the probability that a given 
collision will produce a reaction.  
Taking logarithms of the Arrhenius equation, the following equation can be 
used (Equation 1.4). 
log k=log A-(Ea/2.303)(1/RT)   Equation (1.4)  
   
 
The shelf-life has a reciprocal relationship to the rate constant. In addition, the 
activation energy can be calculated by determining k at a number of 
temperatures and plotting log k against 1/T. The activation energy exemplifies 
the minimum energy required for reactants to undergo a reaction. The higher 
the activation energy, the more temperature-dependent is the reaction (125).  
 
In summary, a good approach to improving the treatment of diabetes is through 
optimising formulations of newly marketed drugs that have shown potential in 
treating diabetes but have formulation-based limitations which compromise 
their efficacy and safety. Such limitations include poor stability and absorption 
profiles. Accordingly, improving diabetes treatment can be achieved by 
studying a new drug that has shown excellent antidiabetic properties in 
controlling insulin release from β-cells, as well as having desirable 
extrapancreatic effects that include slowing down gastric emptying, delaying 
glucose absorption, reducing appetite, weight loss, supressing glucagon 
release in response to eating, as well as anti-toxic effects that help alleviating 
diabetes-associated complications. A good example of such a drug that has 
great extrapancreatic effects in diabetes, but poor stability and an undesirable 
route of administration is exenatide (126-129). 
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1.9 Aim of thesis  
The overall aim of this thesis is to investigate the stability of exenatide in 
aqueous solution. This will be achieved by: 
1. Developing and validating an HPLC stability indicating method. 
2. Investigating the effect of temperature, pH and ionic strength on the 
rate of degradation of exenatide. 
3. Determining if refrigeration of the aqueous solution of exenatide can 
provide an improved shelf-life compared with current formulation.  
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Chapter Two 
 
2 Method Development and Validation 
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2.1 Introduction  
Stability and formulation issues can be addressed through measuring the 
shelf-life, degradation pathways and reaction rate constants at various pH and 
temperature values. This depends on reliable and sensitive analytical methods 
to measure the concentrations of the drug in different solutions. Various 
analytical methods available, including high performance liquid 
chromatography (HPLC) with detection by ultraviolet (UV) spectrophotometry 
or mass spectrometry (MS). The analytical method must be validated for 
specificity, sensitivity, linearity, accuracy, precision (inter- and intra-day 
variation), recovery and stability under the experimental conditions used (130). 
This chapter describes in-depth the development and validation method of an 
HPLC method for the determination of exenatide in solution.  
 
2.2 Exenatide analysis by HPLC 
Materials 
Pure exenatide acetate powder was purchased from Aemon Chemical 
Technology Co. Limited (China) with lot number 141732-76-5 and batch 
number 12AC0816. Exenatide injection 250µg/mL (Byetta®), was purchased 
from Amylin Pharmaceuticals, Inc. (Australia). 
Acetonitrile HPLC grade was purchased from Fisher Scientific (Australia). 
Triethylamine hydrochloride was purchased from Fluka Chemika 
(Switzerland). Trifluoroacetic acid was purchased from SIGMA-ALDRICH 
(USA). The HPLC grade water was purified using a Milli-Q Ultrapure system 
manufactured in Australia by Ibis Technology in Mount Hawthorn Western 
Australia.  The thermometers used in the experiments were the Zeal 
Strengthened 76 mm immersion (England). The water baths were 
manufactured by Grant Instruments (Cambridge) Ltd, Barrington; Cambridge. 
To reduce water evaporation from the water baths, polypropylene spheres 
were used.  The pH meter used in the laboratory was Hanna instruments HI 
8519N (Portugal).  
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The HPLC system consisted of a Waters 501 pump by Millipore, Waters 484 
Millipore tuneable absorbance detector set at 225nm, and Hewlett Packard HP 
3396 Series III Integrator used as a chart recorder. A Vydac 214TP C4, 5um, 
150mm, and 4.6mm column made by Grace Davidson Discovery Sciences 
(USA). The assay was undertaken under isocratic conditions at a flow rate of 
1 mL per minute. Rheodyne, Model 7125 loop injector 20µL (USA). 
 
2.3 HPLC analysis 
The mobile phase consisted of 64% v/v HPLC-grade water, 36% v/v 
acetonitrile, and 0.1% v/v trifluoroacetic acid. Triethylamine hydrochloride was 
added to the mobile phase at a concentration of 10 mM to act as an anti-tailing 
agent. The mobile phase has a pH value of 3.00. The mobile phase was 
thoroughly mixed and filtered using 0.45µm Millipore filter and degassed. 
A stock solution was made using 5mg of exenatide powder in a 100mL 
volumetric flask, made up to volume using Milli-Q water. From this stock 
solution, a series of dilutions were made to produce six concentrations: 2.5, 5, 
10, 12.5, 20 and 25 µg/mL. All the solutions were stored in the refrigerator (2-
8°C) and analysed by HPLC within 24 hour of preparation.  
 
2.4 Method development and validation 
A stability indicating method for measuring exenatide concentrations has been 
developed and validated. Initially, a method developed by Bachhav and Kalia 
was adapted (131). However, it showed a high signal-to-noise ratio and had to 
be refined further. A new method was adapted based on the work of Tsai et al. 
(132). This method was further refined and optimised to enable sensitive, 
accurate, robust and reproducible analysis of the drug in the buffers as well as 
in the marketed formulation. 
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2.4.1 Stability indicating assays 
The stability indicating method was carried out by exposing standard exenatide 
solutions to a range of stress conditions. These conditions included acidic, 
basic, and oxidative environments. The acid stress test was carried out by 
adding 2mL of 0.1M hydrochloric acid (HCl) solution to 2mL of 25µg/mL 
standard exenatide solution. A 40oC temperature was used for all stability 
studies as the standard-reaction temperature because it has been used by 
other studies on exenatide and also it high enough speed up the rate of 
reaction without degrading the drug (133). Degradation studies were not 
carried out at higher temperature to avoid unfolding and consequent thermal 
denaturation of the peptide drug. The mixture was kept in a water bath for 3 
hours and samples were taken at 30 minute intervals. The samples collected 
were treated with the required amount of sodium hydroxide (NaOH) to 
neutralise the acid in the sample to prevent any damage to the column. On the 
other hand, the alkaline stress test was performed by adding 2 mL of 0.1M of 
sodium hydroxide (NaOH) solution to 2mL of 25µg/mL standard exenatide 
solution. The mixture was then kept in a water bath for three hours and 
samples were collected at 30 minute intervals. The collected samples then 
treated with the required amount of hydrochloric acid to neutralise NaOH in the 
sample. For an oxidative stress test, 0.2mL of 30% hydrogen peroxide solution 
(H2O2) was added to 2mL of 25µg/mL standard exenatide solution. The mixture 
was maintained in a water bath for three hours and samples were collected at 
30 minute intervals. All samples were injected immediately onto the HPLC 
system and analysed for exenatide concentrations. All measurements were 
carried out in triplicate, and data are expressed as mean ± SD.  
2.4.2 Linearity measurements 
A calibration curve was constructed to investigate the linearity of the method 
used. Standards were prepared and analysed using six exenatide 
concentrations in buffer, 2.5, 5, 10, 12.5, 20 and 25 µg/ml. Concentrations 
were plotted against Area Under the Curve (AUC). 
A least square fitted line was constructed and all measurements were carried 
out in triplicate and data are expressed as mean ± SD.  
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2.4.3 Precision measurements 
The precision of this method was determined by performing triplicate assays 
on three samples of different concentrations on the same day to confirm 
intraday precision. To confirm inter-day precision, the procedure used in 
intraday validation was used on three different days. From the data collected, 
the mean, standard deviation and the percent relative standard deviation 
(%RSD) were determined. The formula used to calculate %RSD was as 
follows: 
%RSD= Standard deviation / mean x 100  Equation (2.1)  
For the method to be adequately precise for this study, the percent relative 
standard deviation (%RSD) value for the intra and inter day variation should 
be less than 3 %(134).    
2.5 Results 
The method was specific and chromatographic peaks in blank and calibration 
samples were free of interference (Figure 2.1). The retention time for exenatide 
was 3.2 min and the run time was 8 min.  
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2.5.1 Assay Validation 
To identify the exenatide peak in the chromatogram, a sample of 60µg/mL of 
exenatide was injected into HPLC and was compared to a blank injection as 
shown in Figure 2.1. The chromatogram in Figure 2.1(A) shows the retention 
time of exenatide is 3.246 minutes and it is clear of any interference, while 
Figure 2.1 (B) represents a blank injection and only shows the solvent front.  
 
Figure 2.1: Chromatograms representative of exenatide in aqueous solution (A) 
and a Blank run (B).  
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2.5.2 Linearity measurements 
The linearity of the method was validated according to the standards specified 
in the literature (134). All AUC values of the six standard concentrations were 
plotted against the concentration values to produce a standard curve. The 
coefficient of determination (R2) of the line of best fit was 0.987 and the 
intercept was not significantly different from zero. The equation of the slope is 
Y = 7474x+3917. This confirms the linearity of the selected method. The 
standard curve of exenatide is shown in Figure 2.1. 
0 5 1 0 1 5 2 0 2 5 3 0
0
51 0 5
11 0 6
21 0 6
21 0 6
31 0 6
C o n c e n t r a t io n (µ g / m L )
A
U
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Figure 2.1: Standard curve of exenatide (mean ± SD, n=3).  
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2.5.3 Precision measurements 
The other important parameter that was validated in this assay was precision. 
For the three tested concentrations (58µg/mL, 29µg/mL and 14.5µg/mL), the 
intra and inter day readings gave a percentage relative standard deviation 
(RSD) values within the acceptable limit of 3% (134). The values for the intra 
and inter day precision values are shown in Table 2.1.  For days 1, 2 and 3, 
three reading of each concentration was taken and the percentage of the mean 
for each concentration is listed for the corresponding day. The inter-day 
precision for each concentration is then calculated from the mean and the 
standard deviation and are listed in column 5 of Table 2.1.  
 
Table 2.1: Intra and inter day assay precision.  
Conc. 
µg/mL  
Day 1 
% of  
mean 
Day 2 
% of  
mean 
Day 3  
% of 
mean 
Inter-day 
precision  
%RSD 
Intra-day 
precision 
%RSD 
58.0 
29.0 
14.5 
98.6-100.6 
99.5-100.6 
98.8-102 
99.6-101.2 
98.2-102.2 
99.6-101 
99.7-100.3 
99.4-100.5 
99.5-100.7 
     0.3-1.1 
     0.5-2.1 
0.6-1.8 
1.05 
2.74 
0.75 
 
The method was specific and chromatographic peaks in blank and calibration 
samples were free of interference. Standard curve was linear (R2 >0.987) in 
the range 2.5-25 µg/ml (Figure 2.1). The precision of the method was 
established since all the intra and inter day variations were < 3%. 
This chapter presents a selective and reproducible HPLC method for the 
analysis of exenatide. There were no detectable degradation peaks which 
suggests method sensitivity, and the drug was stable throughout the analysis. 
This method, was deployed in the analysis of exenatide concentrations in 
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aqueous solutions at different pH, ionic strength and temperatures (Chapter 
3). 
2.5.4 Experimental variation 
The observed variation in findings including the reaction rate constants was 
possibility due to instrumental error and/or fluctuation of temperature in the 
laboratory. Temperature control during experiments offer an accuracy in the 
range of ± 0.02ᵒC, resulting in maximum error of ±1%. The Hanna pH-meter 
specified an accuracy of ± 0.01 pH unit, therefore the measurement of pH 
involved an error of ± 0.005 of a pH unit. Standardisation techniques could 
introduce an error of ± 0.05. Therefore any measurement could have involved 
a maximum error of ±0.055 of a pH unit. The HPLC analysis of samples 
compared to standards involved a maximum error of ± 3%. Therefore, the 
reaction rate constant could have a maximum error of ±3%. When experiments 
were repeated, the reaction rate constants were reproducible within this range.  
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Chapter Three 
 
3 The effect of temperature, ionic strength and 
pH on the stability and degradation of 
exenatide 
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3.1 Introduction 
Exenatide is currently marketed in injectable formulations, and needs to be 
stored under refrigeration. The stability of these formulations is expected to be 
mainly affected by temperature, ionic catalysis and pH change. In order to 
investigate these effects, exenatide concentrations at various temperatures, 
pH and ionic strength values were investigated. Initially, a wide range of 
temperatures and pH values were examined in order to determine most 
reliable experimental conditions to use for exenatide stability testing. 
Eventually, exenatide concentrations were determined using temperatures of 
35, 40 and 45 oC, and pH values of 2.00, 3.50, 4.50, 6.00, 7.00, 8.00 and 10.00, 
as well as ionic strength effect with different concentrations of sodium chloride 
(50, 100 and 250 mM) at different pH values (2.00, 4.50 and 10.00). These 
values represent a pH value below, near and above the reported isoelectric 
point (pI) of 4.2 (123). Under these experimental conditions, exenatide shelf 
life, rate of degradation and reaction rate constants were measured (Figure 
3.1). The stability of aqueous exenatide solution at actual laboratory 
temperature (20±1 °C) was also examined over a period of 6 weeks. 
 
Figure 3.1: A diagram outlining the study design investigating the effects of 
temperature, ionic strength and pH on the stability of exenatide. 
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3.2 Reaction rate order measurements 
For each experiment, the weighed amount of exenatide was dissolved in the 
specified buffer solution to produce the required concentration. Samples were 
collected for analysis as soon as temperature equilibration occurred (time = 0) 
and then at a regular time intervals. The samples are then analysed by HPLC 
and the logarithm (log10) on the remaining concentration percentage is plotted 
against time to obtain the reaction rate constant for each condition.  
The first order reaction can be expressed in the following equation.  
-dc/dt=kc      Equation (3.1)  
              
In C-ln C0=-kt     Equation (3.2)  
      
log C=log C0-(kt/2.303)    Equation (3.3)   
The linear relationship of Equation 3.3 indicates that a plot of log of the 
remaining concentration percentage against time is linear with a slope (-
kobs/2.303) from which kobs is determined. 
The shelf-life can be calculated using Equation 3.4 for a first order reaction.  
T90=0.105/kobs      Equation (3.4)  
   
3.2.1 Stability indicating HPLC method. 
To determine whether or not the assay method was stability indicating, 
exenatide was subjected to a range of stress conditions to accelerate the 
degradation which included acidic (HCl), alkaline (NaOH) and oxidative stress 
(H2O2) conditions at 40°C. The method was also investigated to ensure the 
separation of the peak from any interference. 
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3.2.2 Acid degradation 
The acid stress test on exenatide was performed as described in section 2.4.1. 
The chromatogram (Figure 3.1) showed the detectable exenatide peaks at zero 
and 180 minutes. There was no interference from any degradants with the 
exenatide peak at the retention time. At the end of the experiment (180 min) 
only 50% of the peak area remained intact. No new peaks or interference with 
the analytical peak was detectable. 
 
Figure 3.1: Chromatograms representative of degradation of exenatide in 0.1M HCl 
(pH 1.00) at 40°C. (A) At zero time and (B) after 180 minutes.  
 
3.2.3 Alkaline degradation  
An alkaline stress test on exenatide was performed as described in section 
2.4.1. As evident from Figure 3.2, exenatide essentially completely degraded in 
the alkaline conditions and new peaks emerged which were not present 
initially. These peaks are degradants of exenatide in the alkaline solution. 
These peaks did not interfere with the exenatide peak.  
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Figure 3.2: Chromatograms representative of degradation of exenatide in 0.1M 
NaOH (pH 13.00) at 40°C. (A) At zero time and (B) After 180 minutes. 
 
3.2.4 Oxidative stress degradation 
The method used to perform the oxidative stress test on exenatide was 
described in section 2.4.1. After 180 minutes, exenatide had completely 
degraded and there was no peak visible, which indicated exenatide was very 
susceptible to oxidation (Figure 3.3).   
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Figure 3.3: Chromatograms representative of degradation of exenatide in 30% H2O2 
at 40°C. (A) At zero time and (B) After 180 minutes. 
 
3.3 Determination of pH rate profile 
Most drugs are salts of either weak acids or bases depending on their pKa 
values. As a result, drug molecules will dissociate partially or completely in 
aqueous solution which will have an effect on the stability of the drug. Often, 
there is general acid-base catalysis and/or specific hydrogen ion [H+] or 
hydroxide ion [OH-] catalysis in aqueous solutions. 
At the lower pH’s, hydrogen ion catalysis is often the predominant reaction, 
while hydroxide ion catalysis is predominant at higher pHs. At the intermediate 
range, the reaction can be catalysed by either hydrogen or hydroxide ion, or it 
can be independent of pH.  The pH stability profile can be obtained from 
plotting the logarithm of the rate constant versus pH. The pH-rate profile has 
different forms which are typical of reactions susceptible to specific acid-base 
catalysis.  
The degradation of exenatide was investigated at different pH values ranging 
from 2.00 to 10.00. The buffers used to achieve these pH values are listed in 
(Table 3.1). The final pH of the buffer was adjusted to the required value after 
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adding exenatide to the solution, to account for any effect on the pH of the 
buffer. The pH of the mixtures were recorded at the start and the end of the 
experiment. There was no significant change in the pH of the mixture over the 
run of the experiments. The concentration of all buffers in this study were 
10mM. The experiments were run until at least 20% of the drug was degraded.   
The rate of degradation of exenatide at each pH was determined from plotting 
the logarithm of the percentage of drug remaining against time. A least squares 
line of best fit was used to fit the slope of the line from which the reaction rate 
constant (kobs) was determined. All the assays were done on triplicates.  
 
Table 3.1: Buffers used in the project 
pH Buffer pKa 
2.00 Chloroacetate buffer   2.88 
3.50 Citrate buffer   3.14 
4.50 Acetate buffer   4.76 
6.00 Citrate buffer   6.39 
7.00 Citrate buffer   6.39 
8.00 Tris buffer   8.06 
10.00 Ethanolamine buffer  9.50 
 
3.3.1 Degradation of exenatide in aqueous solution at pH 2.00.  
The degradation of exenatide at pH 2.00 was studied by adding the drug to 
chloroacetate buffer. The mixture was maintained at 40°C and samples were 
taken and injected onto the HPLC, until the concentration of the drug in the 
solution reached less than 80% of the original concentration and the data 
plotted as shown in Figure 3.4. The reaction rate constant was calculated from 
the slope according to Equation 3.3 and it was 1.44x10-03 h-1 as listed in Table 
3.2.  
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Figure 3.4: Degradation of exenatide at pH 2.00 (n=3, data average ± SD) 
 
 
3.3.2 Degradation of exenatide in aqueous solution at pH 3.50.  
To investigate the rate of degradation of exenatide at pH 3.50, citrate buffer 
(pKa 3.14) was employed. The mixture was maintained at 40°C until at least 
20% of exenatide was degraded. The plotted data showed a linear relationship 
which indicate a first order reaction as shown in Figure 3.5 and the reaction 
rate constant calculated to be 9.73x10-03 h-1.   
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Figure 3.5: Degradation of exenatide at pH 3.50 (n=3, data average ± SD) 
 
3.3.3 Degradation of exenatide in aqueous solution at pH 4.50.  
Acetate buffer (pKa 4.76) was used to investigate the degradation of exenatide 
at pH 4.5 using the method described in section 3.3.1. The plot of the data 
represented a linear relationship indicating a first order reaction with a reaction 
rate constant of 1.15x10-02 h-1. The plot of the data is represented in Figure 
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Figure 3.6: Degradation of exenatide at pH 4.50 (n=3, data average ± SD) 
 
3.3.4 Degradation of exenatide in aqueous solution at pH 6.00 and 7.00.  
To investigate the degradation of exenatide in pH 6.00 and pH 7.00, citrate 
buffer (pKa 6.39) was used and the pH was adjusted using HCl and NaOH to 
arrive at the required pH values. The two exenatide and buffer mixtures were 
placed in water bath at a temperature of 40°C and samples were taken at 
regular intervals. The collected samples were injected onto HPLC and the 
process continued until the remaining concentration exenatide was less than 
80% of the starting concentration. The data for both experiments produced a 
linear relationship which point to a first order reaction rate for both experiments. 
The data for citrate buffer at pH 6.00 is represented in Figure 3.7 and the 
reaction rate constant is 1.05x10-03 h-1. On the other hand, the reaction rate 
constant for pH 7.00 is 2.10x10-03 h-1 and the data represented in Figure 3.8.  
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Figure 3.7: Degradation of exenatide at pH 6.00 (n=3, data average ± SD) 
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Figure 3.8: Degradation of exenatide at pH 7.00 (n=3, data average ± SD) 
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3.3.5 Degradation of exenatide in aqueous solution at pH 8.00.  
The stability of exenatide in pH 8.00 was investigated an evaluated using Tris 
buffer (pKa 8.06) using the method described in section 3.3.1. The data were 
plotted and a linear relationship resulted as shown in Figure 3.9 pointing to a 
first order reaction. The reaction rate constant of the degradation of exenatide 
in a pH 8.00 buffer was 5.50x10-03 h-1 which was calculated from the slope of 
the line of best fit.  
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Figure 3.9: Degradation of exenatide at pH 8.00 (n=3, data average ± SD) 
 
3.3.6 Degradation of exenatide in aqueous solution at pH 10.00. 
The degradation of exenatide was also investigated in pH 10.00 buffer solution 
using ethanolamine (pKa 9.5). The mixture was placed in a hot water bath at 
40°C and samples were collected at a regular intervals. The collected samples 
were analysed using HPLC and the process was repeated until at least 20% 
of the initial exenatide concentration at the start of the experiment degraded. 
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The logarithm of the percentage of the remaining concentration was plotted 
against time as shown in Figure 3.10. Since the plot shows a linear 
relationship, it can be concluded that the degradation of exenatide in pH 10.00 
buffer is first order with a reaction rate constant of 2.05x10-02 h-1.  
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Figure 3.10: Degradation of exenatide at pH 10.00 (n=3, data average ± SD) 
 
The reaction rate constants of the degradation of exenatide in aqueous 
solutions at the investigated pH values are listed in Table 3.2. This clearly 
shows that exenatide is most stable at pH 6.00 with reaction rate constant of 
1.11x10-3 compared to all the investigated pH values while pH 10.00 is the 
least stable with reaction rate constant of 1.89x10-2.  The rate constants are 
also presented graphically in Figure 3.11. 
 
49 
 
Table 3.2: Exenatide reaction rate constants at selected pH values at 40°C.  
pH k h-1 ±SE Shelf-Life (Hour)  
2.00 1.44x10-3 6.91x10-5 72.92  
3.50 9.73x10-3 6.36x10-4 10.79  
4.50 1.15x10-2 4.84x10-4 9.13  
6.00 1.11x10-3 6.91x10-5 94.59  
7.00 2.10x10-3 1.61x10-4 50.00  
8.00 5.40x10-3 4.61x10-4 19.44  
10.00 1.89x10-2 1.18x10-3 5.56  
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Figure 3.11: Graphical presentation of reaction rate constants for selected pH 
values at 40 °C.  
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Figure 3.12: Graphical presentation of log k versus pH.  
The slope of the points from pH 6.00 to pH 10.00 inclusive is 0.33 which is 
significantly different from +1 indicating that the degradation in the alkaline 
region is not a simple hydroxide ion catalysis. Furthermore, the slope indicates 
that more complex reactions are taking place in the degradation of exenatide 
and this may involve multiple degradation pathways taking place at the same 
time. This could relate to the formation of the cyclic intermediate in the pathway 
to deamidation at higher pH values. 
 
On the other hand, there is no clear pattern of degradation under acidic 
condition. The reaction rate appears to increase until the pH reaches 3.50 and 
then remains constant until pH 4.50 before decreasing to the lowest point at 
pH 6.00. This could be due to the changes in the ionisation of the drug as the 
pH changes influencing it rate of degradation. The isoelectric point of 
exenatide is approximately 4.20 (123). The manufacturers of commercially 
available exenatide injection (Byetta®) have formulated its product at pH 4.50, 
which from data in Table 3.2 is less stable than pH 6.00. Exenatide will exist 
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mainly as the protonated species to pH 3.20 and above, where the zwitterionic 
form will predominate from pH 3.20-5.20, above which the anionic form will be 
dominant. It would appear that the zwitterionic form is more reactive than the 
individually charged species.    
3.4 The effect of ionic strength on the rate of degradation of exenatide 
Another facet of the stability of exenatide is the effect of ionic strength on the 
rate of degradation. The effect of ionic strength was investigated by altering 
the ionic concentration in the buffer solutions via the addition of sodium 
chloride (NaCl). The ionic strength of the buffer was calculated using Equation 
1.1. The buffers investigated in this study were chloroacetate (pH 2.00), 
acetate (pH 4.50) and ethanolamine (pH 10.00), and the ionic strengths were 
50, 100 and 250mM. The three ionic strengths of each buffer were placed in a 
water bath at 40°C and samples were collected at regular intervals. The 
collected samples were then injected onto HPLC for analysis and the process 
repeated until less than 80% of the starting exenatide concentration remained 
in solution. The logarithm of the reaction rate constants for each ionic strength 
of each buffer is plotted against the square root of the ionic strength as shown 
in Figure 3.13. The graph shows that there is marginal increase in the 
degradation rate of exenatide as the ionic strength increases. This would imply 
that no species of exenatide is subjected to significant ionic strength effects. A 
value of 3 was added to the values in Figure 3.13 to move them to the positive 
region.  
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Figure 3.13: A plot of the logarithm of the reaction rate constant for the three 
buffers against the square root of the ionic strength of the buffer.  
 
3.5 Temperature dependence studies 
The effect of temperature on exenatide was investigated at three temperatures 
(35, 40, and 45 °C). The pH values selected were pH 2.00, 4.50, and pH 10.00. 
The rate constants (k) were obtained from plotting the log of the remaining 
concentration percentage versus time. The degradation rate at each pH value 
increased with temperature as expected. 
The exenatide solution at pH 2.00, 4.50 and 10.00 were incubated at 35, 40 
and 45°C. Samples were collected at the start of the experiment (time = 0) and 
then at selected time intervals.  
The log of the remaining concentration percentage versus time was plotted for 
each test and the reaction rate constant was obtained. The log of the reaction 
rate constant at each temperature was then plotted against the reciprocal of 
temperature in Kelvin (1/T) to determine the activation energy. The activation 
energy is calculated using the following equation  
Ea=-slope (2.303.R)     Equation (3.5)  
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Table 3.3 shows the rate constant values for pH 2.00, 4.50 and 10.00 at 
temperatures 35, 40 and 45 °C. When the log of the rate constant (log k) is 
plotted against the reciprocal of temperature (1/T) in Kelvin the activation 
energy (Ea) of exenatide is obtained using the Arrhenius plot.  
The plots of the graphs for all temperatures produced linear relationships; 
hence, the degradation of exenatide follows the Arrhenius relationship.  
Table 3.3: The observed rate constants values of exenatide at pH 2.00, 4.5 and 10 
and temperatures 35, 40 and 45 °C.  
Temp. °C k h-1 (pH 2.00) k h-1 (pH 4.50) k h-1 (pH 10.00) 
35 1.20E-03 5.53E-03 8.52E-03 
40 1.38E-03 1.17E-02 2.12E-02 
45 5.52E-03 1.84E-02 2.95E-02 
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Figure 3.14: Graphical presentation of log k versus the reciprocal of temperature 
in kelvin.  
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The activation energy for exenatide at pH 2.00 was calculated using Equation 
3.5 to be 124.0 kJmole-1 as shown in Table 3.4. The activation energy for pH 
4.50 and 10.00 were 121.0 and 138.0 kJmol-1 respectively.  
 
Table 3.4: Activation Energy at selected pH values. Data expressed as mean ± SD, 
n=3. 
                                                                
pH 
                                                                                      
Ea (kJ/mol) 
2.00 124±3 
4.50 121±5 
10.00 138±7 
 
 
The preservative (metacresol) in the marketed formulation of exenatide 
interfered with the analysis so an exenatide formulation was prepared 
identically to that of the marketed formulation, but without metacresol. This 
formulation was left at room temperature (20±1 °C) to investigate exenatide 
degradation. The exenatide solution was studied for 6 weeks with samples 
taken at regular intervals for analysis by HPLC. The data of the study are 
reported in Figure 3.15. The logarithm of the remaining concentration was 
plotted against time. The relationship is linear with R2 of 0.99 and the reaction 
rate constant was calculated and found to be 3.80x10-04 h-1. The pH at which 
the exenatide was formulated was 4.50 to replicate that of the Byetta® 
marketed injection. The shelf-life of exenatide was 276 hours.  
55 
 
0 1 2 3 4 5 6 7
1 .4
1 .6
1 .8
2 .0
2 .2
T im e  (w e e k )
L
o
g
 %
 c
o
n
c
 
Figure 3.15: Six weeks degradation profile of exenatide at room 
temperature (20°C) and pH 4.50. R2=0.99.  
Using the activation energy for pH 4.50 found in (Table 3.4) and the reaction 
rate constant for pH 4.50 from Table 3.3, the theoretical reaction rate constant 
for pH 4.50 at 20 °C was also calculated. The theoretical (extrapolated) 
reaction rate constant calculated to be 4.83x10-4 h-1 which is higher than the 
observed reaction rate constant calculated from the 6 weeks experiment 
(3.80x10-04 h-1), however, there was no significant difference if we calculated 
the theoretical reaction rate constant at the higher end of the activation energy 
(i.e. 126 kJ/mol) which gives a reaction rate constant of 4.24x10-04 h-1. The 
slight improvement in the degradation rate after the six weeks experiment 
compared to the calculated reaction rate constant could be due to the presence 
of mannitol in the formulation of the six weeks experiment which may have a 
stabilising effect of proteins (135). The reaction rate constants for pH 4.50 at a 
selected number of temperatures is listed in Table 3.5. However, compared with 
the calculated shelf life for pH 6.00 (Table 3.6), it is obvious that the shelf-life of 
the formulation at pH 4.50 is markedly lower than if it was formulated at pH 
6.00.  Therefore, it worth doing more research on formulating the drug at pH 
6.00, rather than pH 4.50 to improve its stability and prolong its shelf life.  
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Table 3.5: The reaction rate constants (k) and shelf life (hours) for pH 4.50 and Ea 
(121 kJ/mol) at selected temperatures.  
Temp. (°C) Temp. (Kelvin) k (hr-1) t90(hours) 
2.00 275.15 1.878x10-5 5591.00 
4.00 277.15 2.750x10-5 3818.20 
8.00 281.15 5.805x10-5 1808.10 
20.0 293.15 4.830x10-4 217.40 
25.0 298.15 1.110x10-3 94.59 
30.0 303.15 2.480x10-3 42.00 
35.0 308.15 5.411x10-3 19.41 
40.0 313.15 1.150x10-2 9.13 
45.0 318.15 2.387x10-2 4.40 
 
 
 
 
Table 3.6: The reaction rate constant (k) and shelf life (hours) for pH 6.00 and Ea 
(138 kJ/mol) at selected temperatures.  
Temp. (°C) Temp. (Kelvin) k (hr-1) t90(hours) 
2.00 275.15 7.357x10-7 142721.20 
4.00 277.15 1.137x10-6 92348.28 
8.00 281.15 2.667x10-6 39377.46 
20.0 293.15 2.986x10-5 3516.41 
25.0 298.15 7.716x10-5 1360.81 
30.0 303.15 1.932x10-4 543.50 
35.0 308.15 4.698x10-4 223.50 
40.0 313.15 1.110x10-3 94.60 
45.0 318.15 2.553x10-3 41.13 
 
This chapter also investigated the effects of pH, ionic strength and 
temperature on the stability of exenatide.  
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The pH stability profile shows that degradation rate increases linearly from pH 
6.00 to pH 10.00. However, there is no clear pattern in the acidic region (pH 
2.00 to 6.00) as the rate of degradation is low at pH 2.00 then it rises at pH 
3.50 and peaks at pH 4.50 before dropping to the lowest rate at pH 6.00.  
At the currently marketed formulation (pH 4.50), exenatide shelf-life was 
highest (5591 hr) at refrigeration temperature (2°C) compared with 45oC (4.40 
hr) as expected. At room temperature (25°C), shelf-life was low (94.6 hr) 
suggesting raised degradation outside the refrigerator. Interestingly, the 
stability of exenatide at 40oC (pH 6.00) was significantly higher than at its 
marketed formulation pH 4.50. Compared with pH 4.50, the pH 6.00 
formulation could have a shelf-life of 142721.20 hours (5946.7 days) at 2°C 
while at 25°C it would expire in 1360.81 hours (56.7 days). The pH 6.00 
formulation has a 25.5 fold higher shelf-life compared to the pH 4.50 
formulation at 2°C and 14.4 fold higher at 25 °C. The number fold deference 
between the shelf-lives of exenatide at pH 6.00 and 4.5 widens as the 
temperature decreases. The activation energy of exenatide at pH 6.00 could 
be similar to pH 10.00 since they fall on the same trend line which makes the 
reaction more temperature dependant. Taking into account, the greater 
variation between refrigerated and non-refrigerated temperatures at pH 6.00, 
it still offered a much improved shelf-life compared to pH 4.50. Improving the 
shelf-life of exenatide formulation will makes it more convenient for both 
pharmacies and patients. The shorter shelf-life could lead to the product 
reaching its expiry date before the pharmacy can supply it to patients which 
leads to financial loss. On the other hand, patients who are living or visiting in 
a temperate climate with unreliable access to power will benefit from the longer 
expiry date of the improved formulation.  
At pH 10.00, the reaction rate constant was the highest. The linear relationship 
from pH 6.00 suggests that the degradation is partially catalysed by hydroxide 
ions. Plotting the log of the reaction rate constants versus the pH value from 
pH 6.00 to 10.00 produces a straight line with a slope of 0.33. This is 
significantly lower than 1.00 which is the value expected for the slope of a 
simple hydroxide ion catalysis. This indicated the involvement of multiple 
reaction pathways with different reaction rates in the degradation process. This 
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indicates that the rate of degradation in the alkaline region does not follow 
simple hydroxide ion catalysis but rather more complex reactions involving 
multiple steps and reaction pathways. These degradation pathways most likely 
involve deamidation as well as possibly oxidation and reduction reactions. The 
deamidation reaction is a two-step process and each process has its own rate 
parameters, which are related to the formation of the cyclic intermediate in the 
pathway to deamidation. It is possible that the rate limiting step could vary with 
pH and temperature and that this is one of the reasons that the alkaline 
degradation of exenatide does not follow simple hydroxide ion catalysis.  
As shown in Figure 1.11, exenatide has asparagine (Asn) in its structure which 
is prone to deamidation reactions through the formation of the cyclic 
intermediate (succinimide) and the release of ammonia (113). The presence 
of glycine (Gly) immediately after asparagine in the structure of exenatide 
increases the rate of deamidation of asparagine as Asn-Gly is a sequence with 
the highest reactivity in polypeptides (113, 136). Even though deamidation of 
glutamine is not as common as for asparagine (113), it may still contribute to 
the degradation of exenatide. As previously stated, the plot of the log of the 
reaction rate constant versus pH value from pH 6.00 to 10.00 produced a slope 
of 0.33. This is consistent with published studies showing that an increase in 
the hydroxide ion concentration does not always lead to a proportional 
increase in the rate of deamidation (136).  
Oxidation is the other degradation pathway that can potentially affect any 
proteins containing the amino acids His, Met, Cys, Tyr, and Trp (113). 
Exenatide has three of the above listed amino acids in its structure (His, Met 
and Trp) which makes it potentially susceptible to oxidation. Histidine (His) is 
sensitive to metal-catalysed oxidation and can result in various species with 2-
oxo-His as the main product. This product has been detected in human growth 
hormone, relaxin and prolastin (113). Methionine which is important for 
conformational stability and the function of the protein can be oxidised by 
molecular oxygen to produce a sulfoxide. The rate of oxidation of Met is almost 
independent of pH, however, its rate is increased with increased accessibility 
of the solvent to the residue. The other amino acid in the structure of exenatide 
susceptible to oxidation is Trp, which can be oxidized to produce kynurenine 
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derivatives even in the absence of light, especially when iron-based oxidants 
are present (113). This confirms our findings at section 3.2.4 that exenatide is 
sensitive to oxidation supported by the disappearance of exenatide peak when 
subjected to hydrogen peroxide oxidation.  
The isoelectric point (pI) of exenatide is approximately 4.2 (123). Exenatide 
will exist mainly as the protonated form (cationic) at pH 3.20. From pH 3.20 to 
5.20, the zwitterionic form will predominate, while above pH 5.20 the 
deprotonated form (anionic) will dominate. It would appear the zwitterionic 
form is more reactive, than the individually charged species. Figure 4.1 
shows the different structures of the functional groups of exenatide in 
different pH solutions. 
 
Figure 3.16: The structure of functional groups of exenatide in solutions at different pHs. 
As expected, the rate of degradation of exenatide with increased temperature 
followed the Arrhenius model. Exenatide had the highest activation energy at 
pH 10.00 (138±7 kJ/mol) and the lowest at pH 4.50 (121±5 kJ/mol) which 
suggests that the formulation was most influenced by change in temperature 
at pH 10.00, and was least influenced by change in temperature at pH 4.50. 
Even though our findings showed the activation energy of exenatide to be 
relatively high, it is still comparable with the activation energies of other 
polypeptides such as oxytocin (137, 138). The poly-peptide drug, pramlintide, 
has an activation energy of 21.9 kcal/mol at pH 4.00 which equals to 91.63 
kJ/mol (139) whereas, the activation energy of alteplase is 34.2 kcal/mol which 
equals to 143.2 kJ/mol (140). Furthermore, the activation energy may vary for 
the same peptide drug according to the type of reaction taking place. For 
insulin, the activation energy of neutral deamidation is 80 kJ/mol while the 
aminolysis reactions have an activation energy of 119 kJ/mol (141). Thus, the 
activation energy of a peptide drug can change depending on the pH and the 
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structural conformation. In the case of the anti-stroke peptide, NR2B9c, the 
lowest activation energy is 81.87 kJ/mol at pH 7.50 (Tris buffer) and the highest 
activation energy is 128.37 kJ/mol at pH 8.00 (Tris buffer), due to altered 
reaction mechanism (142). Oxytocin, also has an activation energy of 116.3 
kJ/mol at pH 4.50 (143) which is similar to that of exenatide at the same pH 
value suggesting that our findings are in line with other drug peptides, such as 
oxytocin.   
Ionic strength stability profiles showed that the rate of degradation of exenatide 
did not significantly change when the ionic strength was set at 50, 100 and 
250mM using NaCl at pH 2.00, 4.50 and 10.00. The results suggest that 
changing the ionic strength of the buffer solution does not have a significant 
effect on the rate of degradation within each pH value. This is in line with 
previous studies which have demonstrated little change in degradation 
pathways of protein-drugs at different ionic strength concentrations when pH 
is maintained constant (144-146).  This could also be due to the fact that ionic 
strength does not affect the rate of deamidation of the asparagine residue 
(136).  
The degradation rate of exenatide in the Byetta® replica formulation, over 6 
weeks, when stored at 20±1 °C ( actual laboratory temperature) was slower 
than that extrapolated from the activation energy and the reaction rate constant 
in pH 4.50 buffer at 40°C. However, the difference between the rates of 
degradation were very close to being within the experimental margin of error 
of the activation energy data.  The difference between Byetta formulation and 
the pH 4.50 buffer used, was the presence of mannitol in Byetta, which is an 
osmolarity-regulator. This could be due to the stabilising effect of mannitol 
(135) on the degradation of exenatide or could be due to the slower 
denaturation of the protein. It is possible to exclude the effect of mannitol on 
the stability of exenatide in the future by inclusion of mannitol in all the stability 
studies of exenatide to remove the difference from the marketed formulation.   
The degradants and by products of the degradation reactions were not 
determined, as it is outside the scope of the study.  
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Chapter Four 
 
4 Conclusions and recommendations for 
further research.  
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4.1 Conclusions 
Type 2 diabetes mellitus (T2D) is a complex disease that is characterised by 
uncontrolled glycaemia and is associated with multiple complications including 
toxin build up and compromised gut movement, obesity and high 
cholesterolemia. An excellent antidiabetic drug will be able to exert positive 
antidiabetic effects and will have a convenient route of administration and good 
patient compliance. The oral route is the most convenient for administration 
since dosing is non-invasive and favoured by most patients (147). Clearly, 
good bioavailability and low intra- and inter-patient variability are desirable for 
oral drug delivery.  
Exenatide is a newly marketed antidiabetic drug, for T2D. In addition to its 
insulin-stimulating effects on β-cells of the pancreas, it has many positive 
antidiabetic effects. These positive effects include antioxidant effects, slowing 
gastric emptying rate, appetite reduction, weight loss, suppression of glucagon 
release resulting in optimised glycaemic control as well as protective effects 
on β-cells, which slows down their damage and eventual insulin requirements 
(126-129, 148). 
Exenatide is currently available as injectable formulation which requires 
refrigeration. The requirement for refrigeration is a major limitation to its use, 
especially in countries where refrigeration or power is limited (133). Thus, in 
order to optimise its current formulation, there is a need to investigate the effect 
of temperature on its stability profile. Ideally, this should be investigated and 
optimised in vitro, followed by in vivo preclinical and clinical studies.  
The chemical analysis of peptide-based drugs is often complex and method 
development and validation requires skills to accurately and sensitively isolate 
the analyte from excipients, degradation products, impurities, and matrix 
components. This is in addition to the drug’s potential chirality, secondary 
structures, conformations and the states of any aggregates (149). In the case 
of exenatide, this was further complicated by the potential reactivity, hydrolysis 
or bond-cleavage and racemisation and modifications of the amino acid 
chains. In addition, there is also potential interactions with the containers and 
equipment used, when carrying out sample analysis (133). It is likely that with 
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polypeptides a range of degradation products of various chemical 
characteristics will occur. Hydrophobic chromatographic techniques such as 
RP-HPLC are potentially useful in these separations (150).  Accordingly, in this 
project, multiple RP-HPLC methods for exenatide analysis were initially 
examined. The initial HPLC analysis of exenatide in its marketed injectable 
formulation was unsuccessful due to significant interference from excipients, 
particularly the preservative, meta-cresol. During method development, multi-
gradient mobile phase, double-column separation, gradient-pressure, and 
multiple flow rates were examined. When the pure drug was sourced the 
analytical HPLC-method was further developed, refined and validated before 
a final method was established and the study commenced.   
In chapter two, the validity of the established method for studying the 
degradation of exenatide in aqueous solution was investigated. Reverse phase 
HPLC was used for the analysis of the stability of exenatide. The method was 
examined for its accuracy and precision and for its stability indicating capability 
and the method was suitable for different temperature and pH conditions. The 
method showed good selectivity, sensitivity and results were consistent 
throughout the analysis. However, degradation products were not examined 
as this was outside the scope of this project. 
In chapter three, exenatide was examined at different conditions which include 
different temperatures (35, 40 and 45oC), pH values (2.00, 3.50, 4.50, 6.00, 
7.00, 8.00 and 10.00) and ionic strengths (50, 100 and 250 mM). From that 
study, the reaction rate constants, effect of ionic strength, and the activation 
energies at selected pH values and the shelf-life was determined.  
4.2 Conclusions and recommendation for future directions of research 
In conclusion, it is clear from this study that the lowest degradation rate occurs 
when exenatide is formulated at pH 6.00. Whereas, the highest reaction rate 
constant occurs when exenatide is formulated at pH 10.00. The reaction rate 
constant at pH 4.50 was considerably higher compared to that of pH 6.00 and 
7.00. The shelf-life calculations of exenatide shows a significantly improved 
shelf life when formulated at pH 6.00 compared to pH 4.50.  The manufacturing 
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company has kept all stability data for its product, Byetta, confidential. 
Therefore, the rationale behind formulating Byetta at pH 4.50 instead of pH 
6.00 is speculated to be based on excipient compatibility. Accordingly, future 
research should examine new formulations of exenatide that will provide better 
stability, such as formulating at pH 6.00 instead of 4.50, and a better route of 
administration including sublingual or the oral route which may lead to a better 
patient compliance and a better clinical outcomes. This may include innovative 
technologies such as novel microencapsulation using bile acid-based 
platforms which can offer protection against enzymatic degradation and 
accurately controlling drug release from the microcapsules. This can be 
examined in preclinical as well as clinical studies in T2D.  
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